Visit Capella to learn more about the scientific progress we are making as we translate the science of RNAi into human clinical experience and ultimately towards the development of innovative medicines for patients.
Alnylam has assembled a team of passionate leaders from the biopharmaceutical industry bringing together their collective experiences of drug discovery, drug development, and commercialization.
- John Maraganore, Ph.D., Chief Executive Officer
John Maraganore joined Alnylam in 2002, bringing over 25 years of experience in Research and Development, and business roles with biotechnology companies. Prior to Alnylam he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, Dr. Maraganore was responsible for the company's product franchises in Oncology, Cardiovascular, Inflammation, and Metabolic Diseases. He was previously Vice President, Strategic Planning and M&A and prior to that he was General Manager of Millennium BioTherapeutics, Inc., a former subsidiary of Millennium. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. (now Biogen Idec, Inc.). At Biogen, John invented and led the discovery and development of Angiomax™ (bivalirudin for injection, formerly Hirulog™) currently marketed by The Medicines Company. Prior to Biogen, he was a scientist at ZymoGenetics, Inc., and The Upjohn Company. John received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. Dr. Maraganore is a Director for Agios Pharmaceuticals, Regulus Therapeutics, Tempero Pharmaceuticals, and bluebird bio. In addition, he is an advisor to Third Rock Ventures. John is also a member of the Immunology Advisory Council of Harvard Medical School and a member of the Biotechnology Industry Organization Board.
- Barry Greene, President and Chief Operating Officer
Barry Greene joined Alnylam in 2003, and brings over 20 years of experience in healthcare, pharmaceutical, and biotechnology industries. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE™ (bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Barry served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, his past experiences include Vice President of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Barry received his B.S. in Industrial Engineering from University of Pittsburgh and serves as Senior Scholar at Duke University, Fuqua School of Business. Barry also serves on the Board of Acorda Therapeutics, Inc.
- Laurence Reid, Ph.D., Senior Vice President, Chief Business Officer
Dr. Reid joined in 2010, bringing to Alnylam over 20 years of business development and strategic planning experience within the global biotechnology industry. During his tenure at Ensemble Discovery, he led the development and implementation of key business strategies for the company's therapeutic and diagnostic portfolios, as well as executed major therapeutic discovery alliances with Bristol-Myers Squibb and Pfizer. Prior to that, Laurence worked as a founder of two start-up companies in the fields of stem cell therapeutics and inflammation. He previously spent ten years at Millennium Pharmaceuticals, where he had worked in a range of general management and business development positions. Roles included General Manager of Millennium UK with responsibility for Millennium's European operations, Vice President of Business Development and Strategic Planning for the company's predictive medicine efforts, as well as in pharmaceutical business development and technology acquisition. Before joining Millennium, he was an assistant editor of the journal Cell. Laurence received his Ph.D. from London University and his B.A. from Cambridge University. He also serves as a member of the Board of Directors of The Possible Project.
- Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer
Dr. Vaishnaw joined Alnylam in 2006, coming from Biogen, Inc. (now Biogen Idec Inc.), where he was most recently Senior Director, Translational Medicine. In his seven years at Biogen he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive™) for psoriasis. Akshay received his M.D. from the University of Wales College of Medicine, U.K., with Distinctions in Pathology and Medicine, and his Ph.D. from the University of London, U.K., in Molecular Immunology. He is a Member of the Royal College of Physicians, U.K., and received an Executive M.B.A. from Harvard Business School. In addition, Akshay has published papers in leading scientific journals and authored a number of textbook chapters relating to autoimmune disease.
- Oved Amitay, Vice President, Head of Commercial
Before joining Alnylam in 2012, Mr. Amitay was Vice President for Strategic Development for the Personalized Genetic Health business unit at Genzyme Corporation, now a Sanofi company. At Genzyme, he led the internal research and development activities for their rare diseases franchise. Prior to this position he was General Manager of the Gaucher Disease and MPS Portfolios at Genzyme, where he was responsible for Cerezyme®, leading it to peak sales of over $1.2 billion. Oved joined Genzyme in 1998 and held positions of increasing responsibility in regulatory affairs, medical marketing, market development, and business development in Europe and the Middle East. Prior to joining Genzyme, he was a staff pharmacologist at Peptor Ltd. and Cambridge NeuroScience, Inc. where he was involved in early stage drug development programs. Oved graduated from the School of Pharmacy in the Hebrew University in Jerusalem, and completed his graduate studies in Pharmacology at Northeastern University in Boston.
- Steve Bossone, Ph.D., Vice President, Intellectual Property
Dr. Bossone joined Alnylam 2010 from Shire HGT with over 15 years of experience in the biotech industry. As a Senior Patent Attorney at Shire he provided licensing, acquisition and litigation support as well as strategic input into the life cycle management of several marketed products. Steve began his career at Millennium Pharmaceuticals as a Scientist in the oncology group and then at Millennium Biotherapeutics where he headed the transcript profiling group to support drug discovery initiatives. He transitioned to the Intellectual Property field with positions of increasing authority at Millennium, ToleRx, Serono and Shire. He received his PhD in Molecular Pathology from the lab of Dr. Kenneth Marcu at SUNY Stony Brook (NY) and subsequently worked as a Research Fellow in Medicine in the lab of Dr. Vikas Sukhatme at Harvard Medical School and Beth Israel Hospital. Steve received his JD from Suffolk University School of Law.
- Cynthia Clayton, Vice President, Investor Relations and Corporate Communications
Ms. Clayton joined Alnylam in 2005, where she leads investor and media relations, as well as corporate communications and digital strategies. Prior to joining Alnylam, Cynthia was Director, Investor Relations and Corporate Communications at Synta Pharmaceuticals. In addition, as Senior Manager, Investor and Corporate Communications at Millennium Pharmaceuticals, she worked as part of the team driving the company's strategic communications initiatives, including its first product launch, Velcade. Cynthia began her career in Investor Relations and Corporate Communications at Curis. She earned her B.A. with honors in Communications from the University of Hartford in Connecticut.
- Mary Beth DeLena, Vice President, Associate General Counsel
Ms. DeLena joined Alnylam in 2007 and has served in roles of increasing responsibility in the legal department since that time. She was formerly Vice President, Legal and Secretary at Praecis Pharmaceuticals, where she established and developed the company's legal department, overseeing all corporate legal issues. Prior to that, she worked in the law offices of Skadden, Arps, Slate, Meagher & Flom LLP, where she represented public corporations in ongoing SEC compliance and counseled clients on securities law matters, corporate governance, and other general business matters. Mary Beth received her B.A. in English from Trinity College and her J.D. from Northeastern University School of Law.
- John Frenz, Ph.D., Vice President, Manufacturing
Dr. Frenz joined Alnylam in 2013. Before joining Alnylam, John was Vice President of Operations at GlobeImmune, Inc., where he oversaw clinical supply of seven products across two Phase II and multiple Phase I trials. In addition, he started up GlobeImmune's clinical manufacturing facility and led the design, construction and commissioning of its commercial facility. Prior to GlobeImmune, John was at Genentech, Inc., where he was Plant Manager of Biochemical Manufacturing in South San Francisco. In that role he oversaw the production of all of Genentech's clinical products and about half of its commercial production. John joined Genentech in 1988 and held positions of increasing responsibility in analytical and process development and manufacturing during his 18 years there. John received his B.S. in Chemical Engineering from Yale College, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and his Ph.D. in Chemical Engineering from Yale University. John is a member of the Board of Directors of the California Separation Science Society (CASSS) and the BIO Business Solutions Advisory Board as well as the Permanent Scientific Committees of the Well Characterized Biotechnology Pharmaceutical (WCBP) Symposium and the High-Performance Liquid Chromatography (HPLC) Symposium.
- Jared Gollob, M.D., Vice President, Clinical Research
Dr. Gollob joined Alnylam in 2007 and has been responsible for management of the clinical development organization, in addition to serving in a program leadership role for the company's ALN-VSP program. Prior to Alnylam, he was at Duke University where he was Associate Professor of Medicine and Director of the Biologic Therapy Program, with a secondary appointment as Associate Professor of Immunology. He was also concurrently Head of Hematology/Oncology at the Duke VA Medical Center. Jared received his A.B. and M.D. from Columbia University, and then completed his clinical training at Massachusetts General Hospital, Harvard Medical School, and the Dana-Farber Cancer Institute. Jared is a board certified Medical Oncologist with interests in the immunotherapy of cancer, specifically renal cell carcinoma and melanoma. Previously, he has advised Chiron, Schering-Plough, Bayer, and Novartis on their oncology programs.
- Susanna High, Vice President, Business Planning and Program Management
Ms. High joined Alnylam in 2007 as Senior Director, Business Planning and Program Management. Susanna joined Alnylam from Millennium Pharmaceuticals, Inc., where she most recently was Director of Corporate Strategy and prior to that Director of Business Operations. From 1996 to 2001 she held a leadership role as management consultant with Accenture in their Strategy Pharmaceutical Practice. She has more than 15 years of operations, strategic and financial management experience, locally and internationally. She holds a degree in Economics and Business from Universita' Bocconi, Milan, Italy and a Masters in Business Administration from MIT.
- David Konys, Vice President, Manufacturing Operations
Mr. Konys joined Alnylam in 2003. He was formerly Vice President of Corporate Development at Ingenium Pharmaceuticals AG, and prior to that, had over 15 years of experience at Biogen, Inc. (now Biogen Idec Inc.), where he was the 1995 recipient of the Chairman's Award. During his career, David has been responsible for a wide array of activities related to the building and expansion of growing biotech companies, including establishing a wholly owned subsidiary, Biogen Canada, Inc., for which he was President & Managing Director, licensing intellectual property, directing the expansion of operations groups, and marketing.
- Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery
Dr. Manoharan joined Alnylam in 2003. He was the former Executive Director of Medicinal Chemistry at Isis Pharmaceuticals, Inc., a leading biotechnology company focused on nucleic acid-based therapeutics where he had a12-year tenure. With a distinguished career as a world-leading nucleic acid and bioconjugate chemist, Mano is an author on over 130 publications and over 200 abstracts, as well as the inventor on over 115 issued U.S. patents. Prior to Isis Pharmaceuticals, he earned his Ph.D. in chemistry at the University of North Carolina-Chapel Hill and conducted post-doctoral work at Yale University and the University of Maryland.
- Michael Mason, Vice President Finance and Treasurer
Mr. Mason joined Alnylam in 2005 as Corporate Controller, and has served in roles of increasing financial and operational responsibility since that time. Prior to Alnylam, Mike was at Praecis Pharmaceuticals for five years, most recently as Corporate Controller. He began his career in financial management at KPMG LLP in 1997 where he worked with a variety of public and private audit clients. Mike received his Masters of Business Administration from Babson College and his Bachelors of Business Administration from Stetson University. He is a Certified Public Accountant.
- Rachel Meyers, Ph.D., Vice President, Research and RLD
Dr. Meyers joined Alnylam in 2003 as Associate Director of Research, after having served as a Senior Scientist at Millennium Pharmaceuticals (1999-2003). At Millennium Pharmaceuticals, Rachel was involved in target advancement and the identification, bioinformatic analysis, cloning and functional analysis of novel targets for small molecule drug discovery, antibody development and diagnostic purposes. At Alnylam, she oversees the RNAi Lead Development (RLD) and immunology groups and plays a key role in the development of Alnylam's RNAi therapeutic programs. Rachel holds a degree in Biochemistry from Brandeis University and a Ph.D. in Biology from MIT, and she completed her post-doctoral training at Harvard Medical School. She is a member of the advisory board for the MS program in Biotechnology at Brandeis University.
- Lubomir (Lubo) Nechev, Ph.D., Vice President, Process Sciences
Dr. Nechev joined Alnylam in 2004 and has held roles of increasing responsibility in the process development organization during that time, including the development of manufacturing processes for Alnylam pipeline programs. Prior to joining Alnylam, Lubo worked in the process development department at Transgenomic, Inc., now Agilent Technologies. Before that, he was a scientist at Ribozyme Pharmaceuticals Inc., which became Sirna Therapeutics and was acquired by Merck & Co., Inc. in 2006. Lubo received his B.S., M.S., and Ph.D. in Chemistry from the St. Kliment Ohridski University in Sofia, Bulgaria. He conducted his postdoctoral training at Vanderbilt University in Nashville.
- Saraswathy (Sara) Nochur, Ph.D., Senior Vice President, Regulatory Affairs & Quality Assurance
Dr. Nochur joined Alnylam in 2006 has over 19 years of experience in the areas of product development and regulatory affairs. Most recently, she held the position of Vice President, Regulatory Affairs at The Medicines Company. Prior to her four years there, she served as Director, Product Development and Regulatory Affairs for CereMedix, Inc. Sara also held senior positions at BioTrack, Inc. including Vice President, Product Development and Regulatory Affairs, and Chief Operating Officer. Prior to that she was employed by DynaGen, Inc. where she held positions of increasing responsibility, culminating in the role of Director, New Product Development. Sara received her B.S. and M.S. degrees in Microbiology from the University of Bombay in India, and her Ph.D. in Biochemical Engineering at MIT.
- Michael Placke, Ph.D., DABT, Senior Vice President, Drug Safety and Metabolism
Dr. Placke joined Alnylam in 2013. Before joining Alnylam, Dr. Placke was President and CEO of Ricerca Biosciences, a privately held contract research company, providing integrated non-clinical drug development services to biotechnology and pharmaceutical companies. Prior to Ricerca, Dr. Placke was Vice President of Drug Safety at Wyeth Pharmaceuticals (and at Pfizer after it acquired Wyeth), where he had both operational and portfolio responsibilities for non-clinical drug safety. Before joining Wyeth he was Vice President of Research and Development of a start-up firm developing novel respiratory drug therapies. Dr. Placke has scientific and executive-level operational experience in developing a wide array of drug product modalities including small molecules, biologics, vaccines, and specialty drug products. He is formally trained in experimental pathology and toxicology, earning B.S. and M.S. degrees from The Ohio State University and his Ph.D. from the University of Connecticut. He is board certified in general toxicology, and a recent director and officer of the American Board of Toxicology.
- Eric Raichle, Vice President, Human Resources
Mr. Raichle joined Alnylam in 2007 with over 20 years of global human resources experience with expertise in employee relations, talent management, communication and organizational development. Eric has contributed to the success of several public and private companies including Bain & Company, Digitas LLC, and most recently served as the Director of Human Resources at Alkermes, Inc. He holds a B.A. in Industrial and Organizational Psychology from Suffolk University.
- Aria Tavana, Ph.D., Vice President, Quality Assurance
Dr. Tavana joined Alnylam in 2013. Before joining Alnylam, Dr. Tavana was Senior Director of Process Development and Manufacturing at Momenta Pharmaceuticals, where he was involved in the launch and commercial production of generic enoxaparin, an anticoagulant, as well as the maintenance of an uninterrupted production supply chain spanning China, Europe, and the U.S. In addition, he was involved in the development of candidate drugs for oncology and immunology indications. Prior to Momenta, Aria was at Biogen Idec, where he most recently served as Director of Quality Assurance & Quality Control. In that role he oversaw quality assurance of commercial and clinical product lines, including final drug disposition for human use. Aria joined Biogen in 1995 and held positions of increasing responsibility in process and technical development, supply chain operations, quality assurance, and quality control. Prior to joining Biogen, he was an engineer and project leader in Process Development at Novartis, where he developed chemical engineering unit operations for commercial production. Aria received his B.S. in Chemical Engineering from the University of California, Berkeley, and his Ph.D. in Chemical Engineering from the University of Arizona, Tucson.
- Garvin Warner, Ph.D., Vice President, Pre-Clinical Development
Dr. Warner joined Alnylam in 2010 and has over 19 years of experience in nonclinical drug development. Garvin spent 13 years at Genetics Institute/Wyeth, most recently as an Assistant Vice President/Wyeth Fellow and Therapeutic Area Head within the department of Drug Safety and Metabolism responsible for the immunology and vaccine therapeutic areas. Prior to his role as Therapeutic Area Head, he managed the Exploratory Toxicology group and was the Andover site head for the Drug Safety and Metabolism group. Prior to joining Genetics Institute/Wyeth Gavin was Group Leader of Immunotoxicology within the Department of Biologics Evaluation at Bristol-Myers Squibb. During his career in the pharmaceutical industry, he has been closely involved in all phases of nonclinical drug development and in the successful nonclinical development of 7+ marketed therapeutic proteins/vaccines. Garvin received his Ph.D. in Microbiology and Immunology from Albany Medical College and his A.B. from Colgate University.